Breaking Finance News

Robert W. Baird disclosed GTX Inc (NDAQ:GTXI), hiking its price target to $17.00 earlier today

Having a price of $11.98, GTX Inc (NDAQ:GTXI) traded 0.84% higher on the day. With the last close up 63.27% from the two hundred day average, compared with the Standard & Poor's 500 Index which has increased 0.01% over the same period. GTXI has recorded a 50-day average of $6.44 and a two hundred day average of $5.17. Trade Volume was down over the average, with 35,660 shares of GTXI changing hands under the typical 40,936

Reporting a potential upside of 0.42%, Robert W. Baird upped the price target of GTX Inc (NDAQ:GTXI) to $17.00

On 11/09/2017, Stifel Nicolaus released a statement on GTX Inc (NDAQ:GTXI) upped the target price from $0.00 to $16.00 that suggested an upside of 0.97%.

Recent Performance Chart

GTX Inc (NDAQ:GTXI)

GTX Inc has with a one year low of $0.65 and a one year high of $9.71 and has a market capitalization of $0.

General Company Details For GTX Inc (NDAQ:GTXI)

GTx, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of small molecules for the treatment of cancer, including treatments for breast and prostate cancer, and other medical conditions. The Company is engaged in the development of selective androgen receptor modulators (SARMs). Its lead product candidate, enobosarm (GTx-024), had been evaluated in over 24 completed or ongoing clinical trials, including in approximately six Phase II and two Phase III clinical trials. The Company is also engaged in the development of GTx-758 (Capesaris), an oral nonsteroidal selective estrogen receptor alpha agonist, for secondary hormonal therapy in men with metastatic and high-risk non-metastatic castration resistant prostate cancer (CRPC). Its product candidate, Enobosarm, for the treatment of women with advanced androgen receptor (AR) positive triple-negative breast cancer (TNBC), is in Phase II clinical development-stage.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *